ViiV Healthcare

GSK’s ViiV to expand supply of HIV drug in Africa
BioPharma Dive
Mon, 10/7/24 - 09:47 pm
GSK
ViiV Healthcare
HUV
PrEP
Africa
ViiV Healthcare Premieres Early Data Showing Antiviral Activity Against Integrase Resistance from its Investigational, Third-Generation Integrase Inhibitor VH184
Drugs.com
Wed, 07/24/24 - 10:56 pm
ViiV Healthcare
VH184
ViiV Healthcare reports data from Phase I trial of HIV drug
Clinical Trials Arena
Tue, 03/5/24 - 11:17 am
ViiV Healthcare
HUV
cabotegravir
clinical trials
GSK’s Injectable HIV Drug Bests Pills in Patients with Medication Adherence Issues
BioSpace
Wed, 02/21/24 - 11:17 am
GSK
ViiV Healthcare
clinical trials
Cabenuva
HIV
GSK dials up HIV sales projection to £7B by 2026, updates next-gen launch timelines
Fierce Pharma
Thu, 09/28/23 - 10:45 am
GSK
HIV
Cabenuva
ViiV Healthcare
ViiV Healthcare receives European Commission approval for Apretude
Pharmaceutical Business Review
Wed, 09/20/23 - 08:33 am
ViiV Healthcare
Europe
Apretude
HIV
AIDS
PrEP
GSK's ViiV explores novel pathway to bring long-acting HIV med Cabenuva to tough-to-treat patients
Fierce Pharma
Thu, 07/6/23 - 10:07 pm
GSK
ViiV Healthcare
HIV
Cabenuva
GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill
Yahoo/Reuters
Fri, 02/24/23 - 09:08 am
GSK
HIV
ViiV Healthcare
Gilead Sciences
Cabenuva
Biktarvy
Physician poll finds ultralong-acting regimens and home administration could transform HIV market
Fierce Pharma
Tue, 04/5/22 - 11:02 am
HIV
physicians
GSK
Gilead Sciences
ViiV Healthcare
With competitors circling, ViiV wins another label update for long-acting HIV injectable Cabenuva
Endpoints
Thu, 03/24/22 - 08:33 pm
ViiV Healthcare
GSK
FDA
Cabenuva
HIV
Janssen
Tracking Gilead's 4 Big Stories and a Lawsuit in 2022
Motley Fool
Tue, 02/15/22 - 10:31 am
Gilead Sciences
GSK
legal
ViiV Healthcare
ViiV Healthcare gets FDA nod for two-month dosing of Cabenuva to treat HIV
Pharmaceutical Business Review
Wed, 02/2/22 - 10:57 am
ViiV Healthcare
FDA
HIV
Cabenuva
FDA clears first long-acting HIV-prevention injectable, giving ViiV claim to historic OK
Endpoints
Tue, 12/21/21 - 10:24 am
FDA
HIV
PrEP
Apretude
GSK
ViiV Healthcare
GSK's ViiV looks to future of injectable HIV treatment as long-acting PrEP decision looms
Fierce Pharma
Tue, 11/30/21 - 11:24 pm
ViiV Healthcare
GSK
HIV
PrEP
cabotegravir
GSK's ViiV turns to Black women's experiences in latest season of award-winning podcast
Fierce Pharma
Tue, 11/9/21 - 10:35 am
GSK
ViiV Healthcare
HIV
AIDS
podcasts
pharma marketing
Janssen, Brickell and ViiV are Knocking on FDA's Door
BioSpace
Sat, 10/9/21 - 10:56 pm
FDA
Janssen
Stelara
juvenile psoriatic arthritis
Brickell Bio
sofpironium bromide gel
ViiV Healthcare
HIV
Triumeq
Shionogi licenses out 3rd-gen HIV asset to ViiV, notches a flop in chronic cough
Fierce Biotech
Tue, 09/28/21 - 11:38 pm
Shionogi
HUV
ViiV Healthcare
clinical trials
chronic cough
sivopixant
Gilead challenges ViiV in resistant HIV, filing twice-yearly therapy
Pharmaforum
Tue, 06/29/21 - 10:52 am
Gilead Sciences
HIV
ViiV Healthcare
FDA
lenacapavir
Rukobia
GSK's ViiV, under threat from Gilead-Merck collab, eyes 'ultra-long-acting' HIV drugs with Halozyme deal
Fierce Pharma
Tue, 06/22/21 - 10:47 pm
GSK
ViiV Healthcare
Halozyme Therapeutics
Enhanze
HIV
drug delivery
ViiV begins rolling submission for cabotegravir to prevent HIV in US
Pharmaceutical Business Review
Wed, 05/5/21 - 10:31 am
ViiV Healthcare
cabotegravir
HIV
FDA

Pages